Introduction – A New Chapter in Drug Development The use of biomarkers in medicine is not new....
By Dr Hayley Kain, Pharmacokinetic Scientist at Agilex Biolabs Rapid Data. Smarter Decisions. No...
By Dr. Kurt Sales, CSO Section Summary: How Agilex has emerged as a leader to support the ris...
By Dr. Kurt Sales, CSO Summary The following article focuses on the use of flow cytometry in c...
By William Grenfell, Head of IT In today's digital age, information security is paramount. At Agi...
By Kim Salvatore, Head of Client and Operational Services The bioanalytical and drug development...
There’s a great opportunity for Australian SME’s to take advantage of a well-deserved subsidy!...
Research shows that Biotechnology companies have been facing significant challenges – with continu...
By Dr. Kurt Sales, CSO Introduction Immunological assays are essential in drug development, es...
By Dr. Kurt Sales, CSO Peripheral Blood Mononuclear Cells (PBMC) are critical for the pharmacodyn...
The Role of Peripheral Blood Mononuclear Cells (PBMCs) in Drug Discovery and Clinical Trials. By...
By Dr. Kurt Sales, CSO Oligonucleotides, including small interfering RNA (siRNA) and antisense ol...
By Dr. Kurt Sales, CSO In the high-stakes world of drug development, biotech companies face uniqu...
By Dr. Kurt Sales, CSO Liquid chromatography-mass spectrometry (LCMS) has become an indispensable...
By Dr. Kurt Sales, CSO Preclinical toxicology studies are an essential part of the drug developme...
By Dr. Kurt Sales, CSO Biomarkers are playing an increasingly important role in clinical studies...
by Dr. Kurt Sales, Chief Scientific Officer Liquid chromatography-tandem mass spectrometry (LC-MS...
An exclusive delegation coming from Australia - where leading drug development experts will converge...
Flow cytometry has become a powerful tool in the bioanalytical arsenal. In an era where pharmaceu...
Agilex has offered our clients small molecule solutions that lead to their success. Agilex Biolab...
For 3 decades, Agilex has supported biotech companies with CNS-targeted medicines. For almost 3 d...
Let's face it – we are an aging population throughout the world. More and more, we are seeing thes...
In molecular biology and pharmacology, small molecules are noted for their ability to quickly modula...
Applying Decades of Experience with an Eye on the Future of Small Molecule Development For decade...
Looking beyond the surface on the Complexity of Atopic Dermatitis Addressing inflammatory skin di...
We took some time to sit down and talk with Jason so you could get to know him a bit better... My...
We took some time to sit down and talk with Cameron so you could get to know him a bit better......
We took some time to sit down and talk with Dr Sales so you could get to know him a bit better......
Unraveling the Untapped Potential of Immuno-Oncology Technology Both the pace and varied methods...
A Quick Look at Agilex Biolabs' Expertise and Capabilities In the intricate landscape of drug dis...
Agilex Biolabs has extensive knowledge on small molecule development and pharmacokinetic services....
Agilex Biolabs integrates critical reagents services into comprehensive lifecycle management. The...
Agilex is pleased to introduce Mallory Jolly as our new Senior Business Development Director to the...
Agilex Demystifies the Rapidly Evolving Landscape of Drug Development Post-Covid, the field of bi...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
ddPCR technology provides an opportunity to streamline research and development processes, saving ti...
Small and large molecule drug development often necessitates distinct analytical methodologies. Agil...
Agilex has extensive experience developing and validating like-binding assays for specific immune-on...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stand...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduce...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technol...
by Holly Stefl, Chief Commercial Officer Agilex Biolabs is proud to introduce the West Coast of t...
by Dr. Kurt Sales, Chief Scientific Officer Pharmacokinetics is a key component in a drug develop...
by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, ad...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the C...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent....
Agilex Biolabs, the leading bioanalytical laboratory supporting Australian clinical trials, has established its first satellite processing unit staffed with highly specialised technicians on the fifth floor of the CMAX Clinical Research facility in Adelaide, SA.
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
Rescue studies are a particular point of strength at Agilex Biolabs, where the bioanalytical experts are driven to solve challenges presented by what we call “the weird and wonderful”.
On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards.
Agilex Biolabs, the leading bioanalytical laboratory supporting Australian clinical trials, has established its first satellite processing unit staffed with highly specialised technicians on the fifth floor of the CMAX Clinical Research facility in Adelaide, SA.
Agilex Biolabs has expanded its capacity to better serve the biotech, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility.
Circulating tumor DNA (ctDNA) is tumor-deriver fragmented DNA which originates either directly from the tumor or from circulating tumor cells.
Immunogenicity assessment of biotherapeutics is a regulatory requirement and key parameter for assessing the safety and efficacy of a drug candidate.
Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scient...
Learn how to improve Bioanalytical clinical outcomes by performing MetID characterisation. Leading...
Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory Agilex Biolabs...
Agilex Biolabs provides world-class toxicology services via its purpose-built GLP compliant facility...
This year, we at Agilex Biolabs celebrate our 25th year supporting Biotechs’ d...
Agilex Biolabs Pty Ltd has been purchased by one of Australia’s leading healthcare companies, Healius Limited
With increasingly novel drug development programs, meaningful collection of subject samples has never been more relevant. Don’t let potential analyte instability mislead your program as it gets underway, causing costly time delays
Agilex Biolabs Congratulates VGI Health Technology Limited for successful filing of a new PCT Patent Application on Transmucosal Delivery of Tocotrienols
With the integration of leading toxicology company TetraQ into Agilex Biolabs’ service offering, A...
Meet the Scientists series - Meer Dr Jason Geue, R& D Manager at Agilex Biolabs.
Agilex Biolabs, Australia’s most experienced and technologically advanced bioanalytical laboratory and the only biolab in the region with a dedicated toxicology unit, has been selected as a finalist for the Most Successful Early Phase Research (Preclinical & Phase I) category in the Citeline Awards 2021.
https://youtu.be/dnyLFRPLEJo...
Agilex Biolabs, the Australian specialist bioanalytical and toxicology laboratory facilities for clinical trials is partnering with Endpoints News to share the latest on “Non-clinical and clinical pathways for rapid vaccine development in Australia”, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials is showcasing its new $1.5m vaccine and immunobiology laboratory at BIO Asia Taiwan 2021. The facility, the most sophisticated in APAC, is designed for biotechs and pharma from around the world for advanced clinical research including RNA vaccines, siRNA/miRNA clinical targets and gene therapy studies.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced regulated bioanalytical laboratory for clinical trials today announced that the Premier of South Australia the Hon Steven Marshall MP has launched its new $1.5m vaccine and immuno-biology laboratory. The facility, the most sophisticated in APAC, will attract biotechs and pharma from around the world for advanced clinical research.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Over the past 2 years, Agilex Biolabs has invested more than $3.5m in technology and systems at the APAC headquarters in Adelaide.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials announced for BIO Korea 2021 that their upgraded and expanded biolabs at the Australian headquarters is now complete.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
The labs have been expanded by 30% to cater for increased demand for bioanalysis and biomarkers in clinical studies from clinical stage biotechs.
Inflammation is a complex biological process involving a host of resident and recruited immune cells which are mobilized to infiltrate tissues in response to invading pathogens. These immune cells boast elevated numbers and heightened activation as they churn out inflammatory mediators, which act in unison to coordinate and modulate the immune response.
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Choosing the right bioanalytical platform for your immunology clinical trial is critical to data collection. But navigating the intricate inflammation process can be difficult. What do these platforms look like in use, and how should you go about selecting the right one?
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials is partnering with Endpoints News to share the latest on deconvoluting inflammation and immunology for clinical trials, in a webinar hosted by Endpoints News Editor Arsalan Arif.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, said biotechs with first-in-human studies can leverage significant quality, speed and cost advantages working with their company TetraQ toxicology for pre-clinical research in Australia.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
TetraQ is a NATA-accredited, GLP-recognised rodent toxicology facility.
This webinar examines the hot topics in immunoassay bioanalysis for biotechs navigating the immunogenicity and biomarker requirements for clinical trials. Join the discussion with panelists from Agliex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, and B2S Life Sciences, a biotherapeutic enablement company advancing improved analytical methods and outcomes for developers of biotherapeutic drugs and diagnostics
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced the purchase of leading biolab TetraQ, based out of the University of Queensland.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs CEO Jason Valentine said the Board and senior management at Agilex Biolabs were extremely pleased with the purchase of such a high-calibre bioanalytics company.
“TetraQ complements the Agilex Biolabs work in Australia and APAC with its expert staff and years of experience in regulated bioanalytical services,” he said.
Agilex Biolabs, Australia’s largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
Demand for APAC clinical trials is still on the rise as COVID numbers continue to fall across the region attracting biotechs wanting to restart stalled or paused clinical trials from around the globe. Indeed Australia recorded zero new cases in the past 25 days.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, today announced the roll-out of the GALEXI™ client portal for real-time study management.
Agilex Biolabs is the leading bioanalytical laboratory in Asia-Pacific with the most advanced platforms for sensitive technologies. They include Sciex API 6500+ LC-MS/MS, Sciex API 4000 LC-MS/MS systems; Gyrolab™ Xplore, Luminex MAGPIX xPONENT ™, MSD Quickplex 120 and BD FACSymphony™ A3 20 colour flow cytometry analysers, so we have the capability to deliver any sized project.
Register here (free)...
Agilex Biolabs, the leading APAC biolabs for biotech clinical trials, announced today the launch of a Client Portal named GALEXI™.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
The Agilex Biolabs technology team, with its Microsoft partner, accelerated the launch of GALEXI™ to deliver secure and enhanced communications during continued COVID challenges globally.
Agilex Biolabs, Australia’s most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.
Title: Development and Validation of a PK Method for Tocilizumab in Both Singlicate and Duplicate on the Gyrolab Platform
Agilex Biolabs, Australia’s most advanced specialist bioanalytical laboratory for clinical trials, congratulated client Zelira Therapeutics on their Phase 2 Medicinal Cannabis Insomnia Study.
Why Australia is the World’s Leading Early Phase Destination – Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs Increasingly Sponsors are wanting to be actively involved in the core clinical partner selection because they matter to the success of their clinical research.
Hi, everyone. I'm Arsalan Arif, the publisher of Endpoints News, and I'm pleased to be your moderator today. Today's webinar is sponsored by Agilex Biolabs in Australia. Our topic is Why Australia is the World's Leading Early Phase Destination - Rapid Start-up, No IND Required, and a Government-Backed Refund on Almost Half of all Trial Costs. I'm joined by two great guests today. Kurt Sales, the Director of Immunoassay at Agilex Biolabs, and Jane Kelly, the CEO of CMAX Clinical Research.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for clinical trials, based in Australia, has developed the world’s most accurate cannabinoid assay.
Gathering together the key clinical service providers for a trial can be a daunting process – especially if you are going off-shore to reactivate trials or start new trials to make up for COVID delays.
However, Australia offers a refreshingly streamlined process because of its group of proven top-tier providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities. This makes setting up trials in Australia a smooth, professional, and rapid process for biotechs. This webinar looks at how moving trials to Australia could be much easier than you think.
However, Australia offers a refreshingly streamlined process because of its group of proven top-tier providers that regularly work together so are fully engaged and in sync with processes and each other’s requirements and capabilities. This makes setting up trials in Australia a smooth, professional, and rapid process for biotechs. This webinar looks at how moving trials to Australia could be much easier than you think.
All right. Hi everybody. I’m Arsalan Arif, the publisher of Endpoints News and I’m pleased to be your moderator today. Today’s webinar is sponsored by Agilex Biolabs in Australia and our topic is the Australian Advantage, de-risk your early phase trials. I’m joined by Dr Kurt Sales today with Agilex Biolabs. He’s got an approximately 20 minute presentation and we’re going to follow it up with a quick Q&A. And now I give you Dr Kurt Sales.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, and Endpoints News launched a new webinar “How Easy is it to Move Your Trials to Australia” at BIO Asia-Taiwan 2020.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for clinical trials, encouraged biotechs to consider Australia for their clinical trials during a presentation at BIO Digital 2020.
Agilex Biolabs, Australia’s largest specialist bioanalytical laboratory for biotech clinical trials, is presenting the Australian Advantage including the world’s most attractive rebate on clinical trials costs, at BIO Korea 2020.
The reality is, Australia has fantastic key opinion leaders, some great principal investigators that have been running clinical trials for decades. The CROs, RFA with FDA and EMA requirements. And in fact, our whole Australian service provision industry sets itself to that standard because ultimately that is the client base that Australia is servicing. Most CROs in Australia and service providers will be able to talk about situations where their data has been presented to the FDA or EMA with success.
https://youtu.be/WNdPGkdr9FA...
Video https://www.youtube.com/watch?v=sCUT8qtlRX4&feature=youtu.be...
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed US-based Dr Caroline Popper, MBBS, MPH as Board Chair as part of its APAC clinical trials bioanalytics growth plans.
Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has appointed PhD and NHMRC Fellow Patrick Hughes as R&D Manager Immunobiology.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory based in Australia, announced a raft of new pharmacodynamics services for biotech and pharma clients conducting preclinical and clinical trials in Asia, US, EU and Australia.
Australia-based Agilex Biolabs announced a broad range of new pharmacodynamics services for biopharma clients running preclinical and clinical trials in the U.S., Asia, European Union and Australia.
Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory based in Australia, announced a raft of new pharmacodynamics services for biotech and pharma clients conducting preclinical and clinical trials in Asia, US, EU and Australia.
One of the most important drug development start-up decisions is finding a centrally located bioanalytical laboratory that can support clinical research across all the study locations, and through pre-clinical then potentially for all Phases.
Quality control and consistency of sample management and analysis from early Phase onwards can make a real difference to quality of data and final outcomes.
Quality control and consistency of sample management and analysis from early Phase onwards can make a real difference to quality of data and final outcomes.
Australia-based Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for global clients conducting preclinical and clinical trials, announced at AusBiotech 2019 today it has been selected as a Top 10 Bioanalytical Services Provider by PharmaTech Outlook Magazine (Booth #523).
Boston, MA – Agilex Biolabs, the Asia Pacific’s leading bioanalytical laboratory, announced...
https://youtu.be/UrlJI-Y--k0...
Agilex Biolabs, Australia’s leading bioanalytical laboratory for global clients
conducting preclinical and clinical trials announced at DIA 2019 this week it will analyse more than 60,000 samples in 2019 (June 23-27 San Diego, CA) Booth 2006.
conducting preclinical and clinical trials announced at DIA 2019 this week it will analyse more than 60,000 samples in 2019 (June 23-27 San Diego, CA) Booth 2006.
